Sonia Tabacova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sonia Tabacova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Carole A. Kimmel
National Center for Environmental Assessment, Office of Research and Development, US Environmental Protection Agency, Washington, DC
2 shared publicationsAmarilys Vega
Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA
1 shared publicationDeborah Hansen
National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
1 shared publicationKelly Wall
National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
1 shared publicationRuth Little
National Institute for Environmental Health Sciences, Research Triangle Park, NC, USA
1 shared publicationYi Tsong
Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA
1 shared publication
Latest Publications
- 1 January 2005
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 35 (8-9) , 747-755
Mode of Action: Angiotensin-Converting Enzyme Inhibition—Developmental Effects Associated With Exposure to ACE Inhibitors
Relative to species tested in laboratory studies, the human fetus displays higher vulnerability to enalapril and other angiotensin-converting enzyme inhibitors (ACEI) exhibiting a malformative syndrome that does not appear to have a similar counterpart in experimental animals. An important reason for this higher vulnerability is the earlier intrauterine development of the kidney and the renin-angiotensin-aldosterone (RAS) system in humans, organ systems that are specific targets of ACEI's pharmacological effect. In humans, these systems begin developing prior to the onset of skeletal ossification at the end of the first trimester, with continuing vulnerability throughout the pregnancy. In most animal species tested, these target systems develop close to term, when the fetus is relatively more mature and less vulnerable to the effects of developmental toxicants. For this reason, animal studies that follow standard protocols and evaluate developmental toxicity only for exposures during embryogenesis will miss developmental effects arising secondary to disruption of target systems that develop after the period of major organogenesis. Thus, although the animal mode of action (MOA) for enalapril and other ACEI is plausible in humans, differences in the timing of development of critical target organ systems, particularly the renal system and RAS, explain the absence of definitive structural abnormalities in test animals.
- 1 January 2005
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 35 (8-9) , 747-755
Mode of Action: Angiotensin-Converting Enzyme Inhibition—Developmental Effects Associated With Exposure to ACE Inhibitors
Relative to species tested in laboratory studies, the human fetus displays higher vulnerability to enalapril and other angiotensin-converting enzyme inhibitors (ACEI) exhibiting a malformative syndrome that does not appear to have a similar counterpart in experimental animals. An important reason for this higher vulnerability is the earlier intrauterine development of the kidney and the renin-angiotensin-aldosterone (RAS) system in humans, organ systems that are specific targets of ACEI's pharmacological effect. In humans, these systems begin developing prior to the onset of skeletal ossification at the end of the first trimester, with continuing vulnerability throughout the pregnancy. In most animal species tested, these target systems develop close to term, when the fetus is relatively more mature and less vulnerable to the effects of developmental toxicants. For this reason, animal studies that follow standard protocols and evaluate developmental toxicity only for exposures during embryogenesis will miss developmental effects arising secondary to disruption of target systems that develop after the period of major organogenesis. Thus, although the animal mode of action (MOA) for enalapril and other ACEI is plausible in humans, differences in the timing of development of critical target organ systems, particularly the renal system and RAS, explain the absence of definitive structural abnormalities in test animals.
- 20 March 2003
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 67 (3) , 181-192
Atenolol developmental toxicity: Animal‐to‐human comparisons
BACKGROUND: Atenolol, 4‐2′‐hydroxy‐3′‐isopropyl‐aminopropoxy) phenylacetamide, is a beta‐adrenoreceptor blocker used for treatment of hypertension in pregnancy. Beta‐blockers are reported to cause fetal harm (such as decreased birth weight) when administered to a pregnant woman. We evaluate published human and animal evidence of atenolol developmental toxicity and compare the manifestations in humans and in routinely‐used animal models.METHODS: The comparison is based on the following criteria: comparability of pharmacokinetic/pharmacodynamic characteristics, type of adverse outcome, lowest adverse effect levels, and specificity and selectivity of effect.RESULTS: Manifestations of atenolol prenatal toxicity (placental changes, intrauterine growth retardation and changes in fetal weight in the absence of structural malformations) are similar in the tested animal species (rats and rabbits) and humans. The human seems to be more sensitive, however, because adverse embryo‐fetal effects are reported at doses much lower than those in the tested species. In humans and rats, adverse embryo‐fetal effects are induced by doses that are not maternally toxic. In the rabbit, however, such effects are seen only at maternally toxic doses, suggesting that in this species, developmental toxicity may be maternally mediated.CONCLUSIONS: The available data suggest animal–human concordance with regard to the nature and manifestations of atenolol prenatal toxicity. The animal models “predicted” developmental toxicity manifests as placental changes, intrauterine growth retardation and fetal weight decrease in the absence of structural malformations. Thus far, this is concordant with the data from humans, in whom intrauterine growth retardation has been observed but not structural abnormalities. Birth Defects Research (Part A) 67:181–192, 2003. Published 2003 Wiley‐Liss, Inc.
- 20 March 2003
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 67 (3) , 181-192
Atenolol developmental toxicity: Animal‐to‐human comparisons
BACKGROUND: Atenolol, 4‐2′‐hydroxy‐3′‐isopropyl‐aminopropoxy) phenylacetamide, is a beta‐adrenoreceptor blocker used for treatment of hypertension in pregnancy. Beta‐blockers are reported to cause fetal harm (such as decreased birth weight) when administered to a pregnant woman. We evaluate published human and animal evidence of atenolol developmental toxicity and compare the manifestations in humans and in routinely‐used animal models.METHODS: The comparison is based on the following criteria: comparability of pharmacokinetic/pharmacodynamic characteristics, type of adverse outcome, lowest adverse effect levels, and specificity and selectivity of effect.RESULTS: Manifestations of atenolol prenatal toxicity (placental changes, intrauterine growth retardation and changes in fetal weight in the absence of structural malformations) are similar in the tested animal species (rats and rabbits) and humans. The human seems to be more sensitive, however, because adverse embryo‐fetal effects are reported at doses much lower than those in the tested species. In humans and rats, adverse embryo‐fetal effects are induced by doses that are not maternally toxic. In the rabbit, however, such effects are seen only at maternally toxic doses, suggesting that in this species, developmental toxicity may be maternally mediated.CONCLUSIONS: The available data suggest animal–human concordance with regard to the nature and manifestations of atenolol prenatal toxicity. The animal models “predicted” developmental toxicity manifests as placental changes, intrauterine growth retardation and fetal weight decrease in the absence of structural malformations. Thus far, this is concordant with the data from humans, in whom intrauterine growth retardation has been observed but not structural abnormalities. Birth Defects Research (Part A) 67:181–192, 2003. Published 2003 Wiley‐Liss, Inc.
- 3 January 2003
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 12 (8) , 633-646
Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment
Background: Adverse pregnancy outcomes following the use of angiotensin‐converting enzyme (ACE) inhibitors, including enalapril, have been reported in descriptive studies. However, no analytical studies on the relationship between the adverse outcomes and enalapril gestational exposures are available.Objectives: To explore the association between enalapril exposure and adverse outcomes in pregnancy, taking into account other possible risk factors.Methods: We analyzed a series of all usable cases reported to the FDA between 1986 and 2000 in which enalapril was a suspect drug for the observed adverse outcomes (N = 110). Parameters of exposure and reported outcomes as well as information on potentially confounding variables were systematically abstracted from this series by a single physician. Because exposure to ACE inhibitors after the first trimester of pregnancy had been associated with adverse outcomes in the existing literature, we divided the cases into those exposed in the first trimester only (considered as the baseline group) and cases exposed beyond or after this time. Frequency of reported adverse outcomes in the second group was compared with those in the baseline group; odds ratios were computed, taking account of potentially confounding variables by logistic regression where appropriate.Results: Exposure to enalapril after the first trimester of pregnancy was strongly associated with oligohydramnios and specific adverse outcomes thought to be secondary to reduced amniotic fluid volume (limb deformities, cranial ossification deficits, lung hypoplasia), as well as with neonatal renal failure. The relationship did not change after taking numerous potential confounders into account, including duration of exposure, concomitant drug use, maternal age, concurrent disease, neonatal gender, and gestational age at birth. Such a pattern of abnormalities is considered to be a consequence of the effect of ACE inhibition on fetal renal function that develops after the first trimester.Conclusion: The specificity and temporality of the observed adverse manifestations suggest a causal relationship to enalapril exposure. Copyright © 2003 John Wiley & Sons, Ltd.
- 3 January 2003
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 12 (8) , 633-646
Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment
Background: Adverse pregnancy outcomes following the use of angiotensin‐converting enzyme (ACE) inhibitors, including enalapril, have been reported in descriptive studies. However, no analytical studies on the relationship between the adverse outcomes and enalapril gestational exposures are available.Objectives: To explore the association between enalapril exposure and adverse outcomes in pregnancy, taking into account other possible risk factors.Methods: We analyzed a series of all usable cases reported to the FDA between 1986 and 2000 in which enalapril was a suspect drug for the observed adverse outcomes (N = 110). Parameters of exposure and reported outcomes as well as information on potentially confounding variables were systematically abstracted from this series by a single physician. Because exposure to ACE inhibitors after the first trimester of pregnancy had been associated with adverse outcomes in the existing literature, we divided the cases into those exposed in the first trimester only (considered as the baseline group) and cases exposed beyond or after this time. Frequency of reported adverse outcomes in the second group was compared with those in the baseline group; odds ratios were computed, taking account of potentially confounding variables by logistic regression where appropriate.Results: Exposure to enalapril after the first trimester of pregnancy was strongly associated with oligohydramnios and specific adverse outcomes thought to be secondary to reduced amniotic fluid volume (limb deformities, cranial ossification deficits, lung hypoplasia), as well as with neonatal renal failure. The relationship did not change after taking numerous potential confounders into account, including duration of exposure, concomitant drug use, maternal age, concurrent disease, neonatal gender, and gestational age at birth. Such a pattern of abnormalities is considered to be a consequence of the effect of ACE inhibition on fetal renal function that develops after the first trimester.Conclusion: The specificity and temporality of the observed adverse manifestations suggest a causal relationship to enalapril exposure. Copyright © 2003 John Wiley & Sons, Ltd.